Dr. Carl Spana
and now Vyleesi treat we women Vyleesi Steve. approved sexual you, by is to a XX sexual desire as Vyleesi excited premenopausal needed operational with HSDD The options. a the approval approved FDA by major safe agonist melanocortin women acquired product achievement self-administrated update is and with prior effective the XXst, approximately the as HSDD. I'll a the to Vyleesi. with June the and activity. treatment first-in-class only patient FDA have minutes needed Vyleesi us that as start treatment are for disorder. generalized, for a Thank On is premenopausal hypoactive
of to and launch responsibility sales Pharmaceuticals. Vyleesi believe potential Vyleesi in a In available well scheduled of partner sales Vyleesi. of has national our August, patients made American of is mid-September. to basis a We AMAG drive is the AMAG the presence with strong Vyleesi of health and Vyleesi North are significant Vyleesi that for commercial Commercial female positioned U.S. the late limited AMAG on
America, in regulatory towards are with North has working and filings. our advance global FDA Kwangdong The Pharma; partner, recent South Chinese Vyleesi interest territories of our partner, enter our partners we one believe Korean those accelerated we Outside XXXX. approval Vyleesi of Pharmaceuticals, calendar to Fosun in territories North and will agreements for And are finding that outside we end focusing on more we Vyleesi commercial of licensing or America. into the Vyleesi efforts by licensing development
strategy partnerships focus our programs. major is goal us return to believe our territories. have our on global all Our licensing investment maximize pipeline Vyleesi and Vyleesi to our allow on We will resources for
program primary therapeutic have and our two diseases areas advanced year, of we significantly Palatin's interest, and autoimmune earlier of the past In also melanocortin genetic inflammatory forms stage rare programs. has obesity.
treatment developed receptor diseases. selective and of including We of new other applications families inflammatory a disease, dry bowel melanocortin broad variety retinal autoimmune with potentially eye, inflammatory and of have diseases, in highly uveitis the agonist
melanocortin-X is year, Our In a autoimmune two have and potent receptor we have as Phase for selective applicability inflammatory broad highly agonist, development X believe the and candidate we clinical PL-XXXX PL-XXXX will trials. past completed diseases. which a treatment clinical
a was safety at volunteers. study and PL-XXXX first healthy concerns tolerated doses PL-XXXX no administered well administered subcutaneously were to potential with The dose all noted. ascending and was single multiple
colon oral a treatment to pharmacokinetic a as The this study without can The study from the bowel systemic diseases. PL-XXXX inflammatory clinical that formulation for formulation was of deliver study data oral potential PL-XXXX second exposure. the of dosing an indicates
orphan as to drug treatment FDA the status addition, In PL-XXXX for granted a uveitis. non-infectious
ulcerative which indications, quarter clinical of colitis, PL-XXXX development proof-of-principal current, XXXX. of two the conducting patient which and patients plan for studies clinical will the begin includes will XXXX two fourth half Our uveitis, in in non-infectious enrolling in begin enrollment first
compounds melanocortin-based other diseases. developing for and also We're autoimmune ocular
Our for term and new potentially inflammation. substantially of longer compound patent has in and compound better eye PL-XXXX dry efficacy. providing activity retinal our demonstrated replaces animal PL-XXXX older PL-XXXX excellent models disease
an and required treatment dry developed have drop IND, We of preclinical activities as and drug an clinical formulation file completing a or PL-XXXX application we new to new disease, are eye studies. eye investigational for start potential currently
Phase year. is line with half plan by first begin of the out the reading patient end in and clinical Our study PL-XXXX X the of XXXX to top data enrollment
which supported our in is to programs research the Association, has received selective major patient XXXX. required and centers. the regulatory two system. we trial A X year that approvals two are conjunction with The scheduled done trial anticipate PL-XXXX, Heart research being American by the peptide have in end We enrollment agonist on a is Phase by natriuretic receptor beginning peptide sponsored natriuretic start by
are cardiovascular and results. completed excited still A for by in preclinical, diseases. produced very natriuretic our and liver Although PL-XXXX has studies In and fibrosis the treating fibrosis dual potentially we last of receptor preclinical PL-XXXX, year, encouraging C peptide pulmonary fibrotic a agonist compound
preclinical the fibrotic drug beginning of preclinical Our activities studies if investigation for these file are is complete to studies. models development to plan application additional positive begin efficacy XXXX diseases and required and clinical new to in
can website additional programs on www.palatin.com. on information find You our our
past In the Vyleesi with a investors. year work of put an value. approval and years us dedication closing, hard The major position excellent of company shareholder the to employees for of of grow multiple have our milestone increase the and the is our significant accomplishments results us and of by in support Palatin of
and premenopausal is with Vyleesi the the of women HSDD. treatment addition dealing emotional of to physical significant a impacts
melanocortin In target provides development. as the addition, system validation drug a it of for
into and two New the background by development. the advance FDA, to the Vyleesi we In supporting Drug approval review able Application compounds of were new clinical
by excited impact ocular potential to ocular XXXX. be focused the and PL-XXXX that positively will to forward look treatment and efforts clinical in out programs. half read diseases We're of a disease begin the trial data the will of and development to second Our of PL-XXXX variety of on inflammatory the
allow exciting sheet milestone and maintain strong programs. will Vyleesi efforts a payments from and the to from that receive will balance the and pipeline balance revenue sheet to given maintain royalties continue financing to strong a have and us new support advancement licenses our of Finally, Vyleesi the -- licenses, our us we
you. Thank
We for will now open questions. the call
